155 related articles for article (PubMed ID: 17538878)
1. Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy.
Sankatsing RR; Wit FW; Pakker N; Vyankandondera J; Mmiro F; Okong P; Kastelein JJ; Lange JM; Stroes ES; Reiss P
J Infect Dis; 2007 Jul; 196(1):15-22. PubMed ID: 17538878
[TBL] [Abstract][Full Text] [Related]
2. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
3. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.
Moodley D; Moodley J; Coovadia H; Gray G; McIntyre J; Hofmyer J; Nikodem C; Hall D; Gigliotti M; Robinson P; Boshoff L; Sullivan JL;
J Infect Dis; 2003 Mar; 187(5):725-35. PubMed ID: 12599045
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment.
Shapiro RL; Holland DT; Capparelli E; Lockman S; Thior I; Wester C; Stevens L; Peter T; Essex M; Connor JD; Mirochnick M
J Infect Dis; 2005 Sep; 192(5):720-7. PubMed ID: 16088821
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV.
Chalermchockcharoenkit A; Culnane M; Chotpitayasunondh T; Vanprapa N; Leelawiwat W; Mock PA; Asavapiriyanont S; Teeraratkul A; McConnell MS; McNicholl JM; Tappero JW
Clin Infect Dis; 2009 Jul; 49(2):299-305. PubMed ID: 19522656
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
Tonwe-Gold B; Ekouevi DK; Viho I; Amani-Bosse C; Toure S; Coffie PA; Rouet F; Becquet R; Leroy V; El-Sadr WM; Abrams EJ; Dabis F
PLoS Med; 2007 Aug; 4(8):e257. PubMed ID: 17713983
[TBL] [Abstract][Full Text] [Related]
7. Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1.
Eshleman SH; Hoover DR; Hudelson SE; Chen S; Fiscus SA; Piwowar-Manning E; Jackson JB; Kumwenda NI; Taha TE
J Infect Dis; 2006 Feb; 193(4):479-81. PubMed ID: 16425125
[TBL] [Abstract][Full Text] [Related]
8. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
Krogstad P; Lee S; Johnson G; Stanley K; McNamara J; Moye J; Jackson JB; Aguayo R; Dieudonne A; Khoury M; Mendez H; Nachman S; Wiznia A;
Clin Infect Dis; 2002 Apr; 34(7):991-1001. PubMed ID: 11880966
[TBL] [Abstract][Full Text] [Related]
9. Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
Pérez H; Vignoles M; Laufer N; Gómez A; Coll P; Lottner J; Rolón M; Salomón H; Cahn P
Antivir Ther; 2008; 13(1):135-9. PubMed ID: 18389908
[TBL] [Abstract][Full Text] [Related]
10. Prevention of mother-to-child transmission of HIV in Cameroon: experiences from the University Teaching Hospital in Yaounde (Cameroon).
Kouam L; Nsangou I; Mbanya D; Nkam M; Kongnyuy EJ; Ngassa P; Tebeu PM; Elobe N; Kamgaing NG; Zekeng L; Doh AS
Zentralbl Gynakol; 2006 Apr; 128(2):82-6. PubMed ID: 16673250
[TBL] [Abstract][Full Text] [Related]
11. Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.
Launay O; Gérard L; Morand-Joubert L; Flandre P; Guiramand-Hugon S; Joly V; Peytavin G; Certain A; Lévy C; Rivet S; Jacomet C; Aboulker JP; Yéni P;
Clin Infect Dis; 2002 Nov; 35(9):1096-105. PubMed ID: 12384844
[TBL] [Abstract][Full Text] [Related]
12. Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa.
van Zyl GU; Claassen M; Engelbrecht S; Laten JD; Cotton MF; Theron GB; Preiser W
J Med Virol; 2008 Jun; 80(6):942-6. PubMed ID: 18428139
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe.
Thistle P; Spitzer RF; Glazier RH; Pilon R; Arbess G; Simor A; Boyle E; Chitsike I; Chipato T; Gottesman M; Silverman M
Clin Infect Dis; 2007 Jan; 44(1):111-9. PubMed ID: 17143826
[TBL] [Abstract][Full Text] [Related]
14. Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production.
Franssen R; Sankatsing RR; Hassink E; Hutten B; Ackermans MT; Brinkman K; Oesterholt R; Arenas-Pinto A; Storfer SP; Kastelein JJ; Sauerwein HP; Reiss P; Stroes ES
Arterioscler Thromb Vasc Biol; 2009 Sep; 29(9):1336-41. PubMed ID: 19667106
[TBL] [Abstract][Full Text] [Related]
15. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJ; Schechter M; Murphy RL; Horban A; Hall DB; Lange JM; Reiss P
PLoS Med; 2004 Oct; 1(1):e19. PubMed ID: 15526045
[TBL] [Abstract][Full Text] [Related]
16. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire.
Chaix ML; Ekouevi DK; Rouet F; Tonwe-Gold B; Viho I; Bequet L; Peytavin G; Toure H; Menan H; Leroy V; Dabis F; Rouzioux C;
J Infect Dis; 2006 Feb; 193(4):482-7. PubMed ID: 16425126
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
[TBL] [Abstract][Full Text] [Related]
18. A pilot study to assess the immunologic and virologic efficacy of generic nevirapine, zidovudine and lamivudine in the treatment of HIV-1 infected women with pre-exposure to single dose nevirapine or short course zidovudine and their spouses in Chitungwiza, Zimbabwe.
Zijenah LS; Kadzirange G; Rusakaniko S; Kufa T; Gonah N; Tobaiwa O; Gwanzura C; Matsikire E; Katzenstein DA
Cent Afr J Med; 2006; 52(1-2):1-8. PubMed ID: 17892232
[TBL] [Abstract][Full Text] [Related]
19. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P
AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051
[TBL] [Abstract][Full Text] [Related]
20. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana.
Shapiro RL; Thior I; Gilbert PB; Lockman S; Wester C; Smeaton LM; Stevens L; Heymann SJ; Ndung'u T; Gaseitsiwe S; Novitsky V; Makhema J; Lagakos S; Essex M
AIDS; 2006 Jun; 20(9):1281-8. PubMed ID: 16816557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
